Have you or your loved ones been diagnosed with neoplasm?

You may be eligible to participate in a neoplasm clinical trial.

Have you or your loved ones been diagnosed with neoplasm? You may be eligible to participate in a neoplasm clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Neoplasm Clinical Trial in Detroit MI
NCT01920061 | Phase 1 | Interventional
Pfizer
Sponsored by
Pfizer

Have you or your loved ones been diagnosed with neoplasm?

You may be eligible to participate in a neoplasm clinical trial.

Have you or your loved ones been diagnosed with neoplasm? You may be eligible to participate in a neoplasm clinical trial.

Completed

Male & Female

18 Years +

This study has recruited 110 Participants

This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer in order to determine the maximum tolerated dose in each combination. The cisplatin combination expansion portion will evaluate the anti tumor activity of PF 05212384 plus cisplatin in patients with TNBC in 2 separate Arms (Arm 1 and Arm 2).